PATENT CLAIM ANALYSIS

Application Number: 15989360
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["544", "358000"]

Abstract:
This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.

Claim (Index 6):
The method of  claim 1 , wherein said PCSK9 protein allosteric inhibitor ligand increases the population of low density lipoprotein receptors measurable on the cell surface of said plurality of hepatocytes.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 93.0
- Lexical Diversity: 1.71605
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15505017', '15753790', '14825700', '15558491', '15431568']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7862701075653534
- 35 USC 102 Novelty (BERT): 0.6274528531243341
- Combined Prediction Score: 0.7703883821212515
- Mean Citation Score: 449.608288
- Max Citation Score: 640.1795
- Similarity Product: 507.7123190605044

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test